Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ame Company For Medical Supplies (9527.SR)
Jeddah, Makkah Province, SA
Ame Company For Medical Supplies operates as a distributor and marketer of medical products specifically designed for the aesthetic market throughout Saudi Arabia. Its comprehensive product catalog features a variety of key offerings, including Teoxane, a line of injectable hyaluronic acid-based dermal fillers formulated to reduce wrinkles on the face and neck. The company also provides advanced medical laser systems, innovative therapeutic solutions, and various botulinum products. Furthermore, their portfolio encompasses Magellan, an autologous concentration system for delivering focused platelets and cells at the point of care, as well as MINT, an absorbable polydioxanone barbed suture used for soft tissue approximation. Established in 2005, the firm is headquartered in Jeddah, Saudi Arabia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -2.99% | -26.44% | -25.02% | -18.00% | -31.67% | +75.45% | +19.85% | +19.85% | +19.85% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-10 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Distribution: +5.6%+22.8% ★ Q4'25: +150.6% (vs Q3'24)
-
EPS growth Medical - Distribution: +4.9%-23.0% Q4'25: -24.6% (vs Q3'24)
-
FCF margin FCF growth · Medical - Distribution: +37.6%-12.5% Q4'25: -14.5% (vs Q3'24)
-
EBIT margin Medical - Distribution: +3.0%+14.1% ★ Q4'25: +40.6% (vs Q3'24)
-
ROIC Medical - Distribution: +5.7%+21.8% ★
-
Share dilution Medical - Distribution: +0.0%+0.0% Q4'25: +0.1% (vs Q3'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×0.65× ★ Q4'25: 0.12× (vs Q3'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. |
|---|---|---|---|---|
| Revenue |
248.35M
est: 276.37M (-10.1%)
|
304.96M
est: 79.73M (+282.5%)
|
91.46M
91.46M – 91.46M
+14.7% YoY
|
391.00M
391.00M – 391.00M
+327.5% YoY
|
| EBITDA |
52.04M
est: 39.48M (+31.8%)
|
42.90M
est: 11.39M (+276.7%)
|
13.07M
13.07M – 13.07M
+14.7% YoY
|
55.86M
55.86M – 55.86M
+327.5% YoY
|
| EBIT |
50.21M
est: 39.87M (+26.0%)
|
42.90M
est: 11.50M (+273.0%)
|
13.19M
13.19M – 13.19M
+14.7% YoY
|
56.40M
56.40M – 56.40M
+327.5% YoY
|
| Net Income |
45.40M
|
35.01M
est: 49.85M (-29.8%)
|
58.82M
58.82M – 58.82M
+18.0% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
55.18M
est: 42.23M (+30.7%)
|
—
est: 12.18M (-100.0%)
|
13.98M
13.98M – 13.98M
+14.7% YoY
|
59.75M
59.75M – 59.75M
+327.5% YoY
|
| EPS |
6.49
|
5.00
est: 7.12 (-29.8%)
|
8.40
8.40 – 8.40
+18.0% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-21 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-17 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-10 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-05 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-04 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-03 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-26 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-19 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ali Mohammed deeb Ali Eid | MD & Director | 240.0K | male |
| Abd al-Fattah Ahmed | Chief Executive Officer | — | — |
| Ahmed Hamdi Mohamed Al-Saeed | Chief Financial Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 9527.SR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
